ABVX 4분기 급등

ABVX Q4 momentum is unsustainable and represents a speculative bubble; stock will decline 30% or more within 120 days as investors realize lack of fundamental earnings support or pipeline advancement.

The Q4 surge reflects increased institutional investor interest, evidenced by trading volume spike and analyst upgrades that will result in analyst consensus price target increasing by at least 40% within 90 days post-surge.

ABVX's Q4 58% surge is driven by positive clinical trial results or regulatory approval catalyst that will sustain momentum into Q1, resulting in stock price remaining above Q4 closing levels with at least 25% premium over pre-surge baseline.